Mayo Clinic | Hypertrophic cardiomyopathy guideline update: Mayo Clinic's perspective @MayoClinic | Uploaded August 2024 | Updated October 2024, 6 days ago.
Mayo Clinic medical experts in hypertrophic cardiomyopathy, Jeffrey B. Geske, M.D., Steve R. Ommen, M.D., and Hartzell V. Schaff, M.D., discuss the recent publication of the "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy." 

They review the top changes to the guideline, including the introduction of a cardiac myosin
inhibitor, mavacamten, for support of people with symptomatic obstructive hypertrophic cardiomyopathy (HCM); the evolved guidelines for healthy levels of exercise; the formal split in sudden cardiac death risk assessment between children and adults living with HCM; and new advice on more frequent screening for individuals who have risk factors for atrial fibrillation. 

Learn more, mayoclinic.org/diseases-conditions/hypertrophic-cardiomyopathy/care-at-mayo-clinic/mac-20350208

From Mayo Clinic to your inbox, sign-up for free: mayocl.in/3e71zfi

Visit Mayo Clinic: mayoclinic.org/appointments?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=TNSvQBCdu4U&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504

Like Mayo Clinic on Facebook: facebook.com/mayoclinic
Follow Mayo Clinic on Instagram: instagram.com/mayoclinic
Follow Mayo Clinic on X, formerly Twitter: https://x.com/MayoClinic
Follow Mayo Clinic on Threads: threads.net/@mayoclinic